AVALO THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
AVALO THERAPEUTICS, INC. (AVTX) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 34.77 million shares for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2020-03-11
- AVALO THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2018-06-30 was 32.25M shares, a 143.07% increase year-over-year.
- AVALO THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2018-03-31 was 31.32M shares, a 206.54% increase year-over-year.
- AVALO THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2017-06-30 was 13.27M shares, a 53.36% increase year-over-year.
- AVALO THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2017-03-31 was 10.22M shares, a 18.10% increase year-over-year.
- AVALO THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 34.77M shares.
- AVALO THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2016 was 8.83M shares, a 296.69% increase from fiscal 2015.
- AVALO THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2015 was 2.23M shares, a 246.70% increase from fiscal 2014.
- AVALO THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2014 was 642.05K shares, a 1.32% increase from fiscal 2013.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2018-12-31 | 34.77M shares 10-K · filed 2020-03-11 | |||
| 2018-06-30 | 32.25M shares 10-Q · filed 2018-08-09 | 31.78M shares 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | 31.32M shares 10-Q · filed 2018-05-11 | |||
| 2017-06-30 | 13.27M shares 10-Q · filed 2018-08-09 | 11.70M shares 10-Q · filed 2018-08-09 | 10.92M shares derived: average of 3 quarters · filed 2018-08-09 | 10.38M shares derived: average of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | 10.22M shares 10-Q · filed 2018-05-11 | 9.74M shares derived: average of 2 quarters · filed 2018-05-11 | 9.41M shares derived: average of 3 quarters · filed 2018-05-11 | 9.22M shares derived: average of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | 9.26M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | 9.01M shares derived: average of 2 quarters · filed 2017-03-14 | 8.89M shares derived: average of 3 quarters · filed 2017-08-14 | 8.83M shares 10-K · filed 2017-03-14 |
| 2016-09-30 | 8.76M shares 10-Q · filed 2016-11-08 | 8.70M shares derived: average of 2 quarters · filed 2017-08-14 | 8.69M shares 10-Q · filed 2016-11-08 | 8.25M shares derived: average of 4 quarters · filed 2017-08-14 |
| 2016-06-30 | 8.65M shares 10-Q · filed 2017-08-14 | 8.65M shares 10-Q · filed 2017-08-14 | 8.09M shares derived: average of 3 quarters · filed 2017-08-14 | 6.23M shares derived: average of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | 8.65M shares 10-Q · filed 2017-05-09 | 7.80M shares derived: average of 2 quarters · filed 2017-05-09 | 5.42M shares derived: average of 3 quarters · filed 2017-05-09 | 4.23M shares derived: average of 4 quarters · filed 2017-05-09 |
| 2015-12-31 | 6.95M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | 3.80M shares derived: average of 2 quarters · filed 2017-03-14 | 2.75M shares derived: average of 3 quarters · filed 2017-03-14 | 2.23M shares 10-K · filed 2017-03-14 |
| 2015-09-30 | 649.72K shares 10-Q · filed 2016-11-08 | 649.72K shares derived: average of 2 quarters · filed 2016-11-08 | 649.72K shares 10-Q · filed 2016-11-08 | 648.04K shares derived: average of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | 649.72K shares 10-Q · filed 2016-08-15 | 649.72K shares 10-Q · filed 2016-08-15 | 647.48K shares derived: average of 3 quarters · filed 2017-03-14 | 647.33K shares derived: average of 4 quarters · filed 2017-03-14 |
| 2015-03-31 | 649.72K shares 10-Q · filed 2016-05-16 | 646.36K shares derived: average of 2 quarters · filed 2017-03-14 | 646.53K shares derived: average of 3 quarters · filed 2017-03-14 | |
| 2014-12-31 | 643.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | 644.93K shares derived: average of 2 quarters · filed 2017-03-14 | 642.05K shares 10-K · filed 2017-03-14 | |
| 2014-09-30 | 646.86K shares 10-Q · filed 2015-11-13 | 641.74K shares 10-Q · filed 2015-11-13 | ||
| 2013-12-31 | 633.67K shares 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |